Discussion on development strategy and progress of mesenchymal stem cell products from pharmacy perspective

Abstract

Abstract: The stem cell products has been transforming from research into drug therapy, which will benefit from traditional pharmaceutical ideas. Taking mesenchymal stem cells(MSCs) products as an example, this paper discusses the problems restricting the development of stem cell products from the perspectives of various pharmaceutical disciplines, such as medicinal chemistry, pharmaceutics, pharmaceutical analysis and pharmacokinetics, so as to provide a new strategy and pathway for the development of stem cell products in the future.

Key words: mesenchymal stem cell, cell drug, pharmaceutical science

CLC Number:

R329

LI Xiao-jing,WANG Li,ZHAO Chun-hua,LIU Ren-min,MA Sheng-jun,LI Guang-yao,REN Shao-da. Discussion on development strategy and progress of mesenchymal stem cell products from pharmacy perspective[J]. Basic & Clinical Medicine, 2021, 41(9): 1338-1341.

References

[1]Brown C, McKee C, Bakshi S, et al. Mesenchymal stem cells: cell therapy and regeneration potential[J]. J Tissue Eng Regen Med, 2019, 13: 1738-1755.
[2]Pittenger MF, Discher DE, Peault BM, et al. Mesenchymal stem cell perspective: cell biology to clinical progress[J]. NPJ Regen Med, 2019, 4: 22. doi: 10.1038/s41536-019-0083-6.
[3]Guadix JA, Lopez-Beas J, Clares B, et al. Principal criteria for evaluating the quality, safety and efficacy of hMSC-based products in clinical practice: current approaches and challenges[J]. Pharmaceutics, 2019, 11: 552. doi: 10.3390/pharmaceutics11110552.
[4]Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application[J]. Stem Cells Int, 2018, 2018: 3057624. doi:10.1155/2018/3057624.
[5]Yousefi F, Lavi Arab F, Nikkhah K, et al. Novel approaches using mesenchymal stem cells for curing peripheral nerve injuries[J]. Life Sci, 2019, 221: 99-108.
[6]Poltavtseva RA, Poltavtsev AV, Lutsenko GV, et al. Myths, reality and future of mesenchymal stem cell therapy[J]. Cell Tissue Res, 2019, 375: 563-574.
[7]Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia[J]. Aging Dis, 2020, 11: 216-228.
[8]Mo M, Wang S, Zhou Y, et al. Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential[J]. Cell Mol Life Sci, 2016, 73: 3311-3321.
[9]Najar M, Bouhtit F, Melki R, et al. Mesenchymal stromal cell-based therapy: new perspectives and challenges[J]. J Clin Med, 2019, 8: 626. doi:10.3390/jcm8050626.
[10]Ocansey DKW, Pei B, Yan Y, et al. Improved therapeutics of modified mesenchymal stem cells: an update[J]. J Transl Med, 2020, 18: 42. doi: 10.1186/s12967-020-02234-x.
[11]Kim DS, Jang IK, Lee MW, et al. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-gamma[J]. EBioMedicine, 2018, 28: 261-273.
[12]Huang XP, Ludke A, Dhingra S, et al. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart[J]. FASEB J, 2016, 30: 3069-3082.
[13]Yin N, Wang Y, Ding L, et al. Platelet-rich plasma enhances the repair capacity of muscle-derived mesenchymal stem cells to large humeral bone defect in rabbits[J]. Sci Rep, 2020, 10: 6771. doi: 10.1038/s41598-020-63496-5.
[14]Vasile C, Pamfil D, Stoleru E, et al. New developments in medical applications of hybrid hydrogels containing natural polymers[J]. Molecules, 2020, 25:1539. doi: 103390/molecules25071539.
[15]Deak E, Ruster B, Keller L, et al. Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice[J]. Cytotherapy, 2010, 12: 260-264.
[16]Gurung S, Deane JA, Darzi S, et al. In vivo Survival of human endometrial mesenchymal stem cells transplanted under the kidney capsule of immunocompromised mice[J]. Stem Cells Dev, 2018, 27: 35-43.
[17]Andrzejewska A, Jablonska A, Seta M, et al. Labeling of human mesenchymal stem cells with different classes of vital stains: robustness and toxicity[J]. Stem Cell Res Ther, 2019, 10: 187. doi: 10.1186/s13287-019-1296-8.
[18]Dhada KS, Hernandez DS, Suggs LJ. In vivo photoa-coustic tracking of mesenchymal stem cell viability[J]. ACS Nano, 2019, 13: 7791-7799.
[19]Mohseni M, Shojaei S, Mehravi B, et al. Natural polymeric nanoparticles as a non-invasive probe for mesenchymal stem cell labelling[J]. Artif Cells Nanomed Biotechnol, 2020, 48: 770-776.
[20]Brooks A, Futrega K, Liang X, et al. Concise review: quantitative detection and modeling the in vivo kinetics of therapeutic mesenchymal stem/stromal cells[J]. Stem Cells Transl Med, 2018, 7: 78-86.
[21]Fabian C, Naaldijk Y, Leovsky C, et al. Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health[J]. Stem Cell Res Ther, 2017, 8: 85. doi: 10.1186/s13287-017-0533-2.